EGFR and P-GP expression in oropharyngeal mucosa in relation to smoking

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1639-1648

  Baumeister, Philipp ^a   Märte, Melanie ^a   Reiter, Maximilian ^a   Welz, Christian ^a   Schwenk Zieger, Sabina ^a   Harreús, Ulrich ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

EGFR; HNSCC; Oropharyngeal mucosa; P glycoprotein; Smoking; TGF a

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OROPHARYNX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; TISSUE CULTURE;

ADOLESCENT; ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; OROPHARYNGEAL NEOPLASMS; OROPHARYNX; P-GLYCOPROTEIN; PAPILLOMAVIRIDAE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84861516445     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet 371: 1695-1709, 2008. (Pubitemid 351671886)
2. Leemanns CR, Braakhuis BJM and Brakenhoff RH: The molecular biology of head and neck cancer. Nature Rev Cancer 11: 9-22, 2011.
3. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH and Gillison ML: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944-1956, 2007. (Pubitemid 46740304)
4. Munger K and Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res 89: 213- 228, 2002.
5. International Agency for Research on Cancer (IARC): Tobacco smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 38. IARC Press, Lyon, France, 1998.
6. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, Sitas F, Smith J, Stayner L, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze D, Peto R and Doll R: Tobacco and cancer: recent epidemiological evidence. JNCI 96: 99-106, 2004. (Pubitemid 38195900)
7. Slaughter DP, Southwick HW and Smejkal W: Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6: 963-968, 1953.
8. Wells A: EGF receptor. J Biochem Cell Biol 31: 637-641, 1999.
9. Ozanne B, Richards CS, Hendler F, Burns D and Gusterson B: Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 149: 14, 1986.
10. Kalyankrishna S asnd Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 17: 2666-2672, 2006.
11. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002. (Pubitemid 36025259)
12. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28, 2010.
13. Christen RD, Hom DK, Porter DC, Andrews PA, MacLeod CL, Hafstrom L and Howell SB: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 86: 1632-1640, 1990. (Pubitemid 20372614)
14. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK and Perez- Soler R: Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 11: 1572-1578, 2005.
15. Hiraishi Y, Wada T, Nakatani K, Tojyo I, Matsumoto T, Kiga N, Negoro K and Fujita S: EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines. Pathol Oncol Res 14: 39-43, 2008.
16. Baumeister P, Reiter M, Schwenk-Zieger S and Harréus U: Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin. Chemotherapy 56: 268- 274, 2010.
17. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N and Hitt R: Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127, 2008.
18. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A and Eckardt A: Phase ll multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinumbased chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568-5577, 2005.
19. Grandis JR and Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584, 1993. (Pubitemid 23229640)
20. Grandis JR, Melhem MF, Barnes EL and Tweardy DJ: Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78: 1284-1292, 1996. (Pubitemid 26303896)
21. Shin DM, Ro JY, Hong WK and Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159, 1994. (Pubitemid 24208920)
22. Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, Jinawath, N, Tsai MH, Chang NW, Lin CF, Lin CC, Hsieh LJ, Wang TL, Shih IM and Tsai FJ: Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 69: 2568-2576, 2009.
23. Reiter M, Welz C, Baumeister P, Schwenk-Zieger S and Harréus U: Mutagen sensitivity and DNA repair of the EGFR gene in oropharyngeal cancer. Oral Oncol 46: 519-524, 2010.
24. International Agency for Research on Cancer (IARC): Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 92. IARC Press, Lyon, Francy, 2010.
25. Baumeister P, Schwenk-Zieger S, Reiter M, Welz C and Harréus U: Transforming Growth Factor-alpha reduces carcinogen-induced DNA damage in mini-organ cultures from head-and-neck cancer patients. Mutat Res 677: 42-45, 2009.
26. Baumeister P, Heinrich K, Märte M, Reiter M, Schwenk-Zieger S and Harréus U: The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro. Oral Oncol 47: 1141-1147, 2011.
27. Sarkadi B, Homolya L, Szakács G and Váradi A.: Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236, 2006. (Pubitemid 44521651)
28. Kelley DJ, Pavelic ZP, Gapany M, Stambrook P, Pavelic L, Gapany S and Gluckman JL: Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 119: 411-414, 1993. (Pubitemid 23110080)
29. Ralhan R, Swain RK, Agarwal S, Kaur J, Nath N, Sarkar G, Mathur M and Shukla NK: P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer 84: 80-85, 2000. (Pubitemid 29059113)
30. Wamakulasunya S, Jia C, Johnson N and Houghton J: P53 and p-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. J Pathol 191: 33-38, 2000. (Pubitemid 30235646)
31. Friedrich RE, Punke C and Reymann A: Expression of multidrug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma. In Vivo 18: 133-148, 2004. (Pubitemid 38488996)
32. Zhigang H, Qi Z, Jugao F, Xiaohong C, Wei Z, Hong W, Hu H, Na M, Zheng Y and Demin H: Reverse multidrug resistance in laryngeal cancer cells by knockdown MDR1 gene expression. J Otolaryngol Head Neck Surg 38: 440-448, 2009.
33. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE and Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Aca Sci USA 94: 4028- 4033, 1997.
34. Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Serpico R, Rubini C, Fioroni M, Fanali S, Piattelli A: The human multidrug resistance gene (MDR-1): immunocytochemical detection of its expression in oral SCC. Anticancer Res 20: 2891-2897, 2000.
35. Uematsu T, Hasegawa T, Hiraoka BY, Komatsu F, Matsuura T, Yamada AS and Yamaoka M: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer 15: 187-194, 2001. (Pubitemid 32225368)
36. Chin KV, Chauhan SS, Pastan I and Gottesman MM: Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1: 361-365, 1990.
37. Chin KV, Tanaka S, Darlington G, Pastan I and Gottesman MM: Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265: 221-226, 1990.
38. Yeh GC, Lopaczynska J, Poore CM and Phang JM: A new functional role for P-glycoprotein: efflux pump for benzo(alpha)pyrene in human breast cancer MCF-7 cells. Cancer Res 52: 6692-6695, 1992.
39. Myllynen P, Kurttila T, Vaskivuo L and Vähäkangas K: DNA damage caused by benzo(a)pyrene in MCF-7 cells is increased by verapamil, probenecid and PSC833. Toxicol Lett 169: 3-12, 2007. (Pubitemid 46215948)
40. Ferguson LR and Baguley BC: Multidrug resistance and mutagenesis. Mutat Res 285: 79-90, 1993. (Pubitemid 23029557)
41. Ferguson LR and De Flora S: Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res 591: 24-33, 2005. (Pubitemid 41654837)
42. Sam SS, Thomas V, Sivagnanam K, Reddy KS, Surianarayanan G and Chandrasekaran A: ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. Pharmacogen Genomics 17: 861-866, 2007. (Pubitemid 47462299)
43. Rohlff C and Glazer RI: Topical review - regulation of multidrug resistance through the cAMP and EGF signalling pathway. Cell Signal 7: 431-443, 1995.
44. Scotto KW: Transcriptional regulation of ABC drug transporters. Oncogene 22: 7496-7511, 2003.
45. Yang JM, Vassil AD and Hait WN: Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60: 674- 680, 2001.
46. Yang JM, Sullivan GF and Hait WN: Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol 53: 1597-1604, 1997. (Pubitemid 27356088)
47. Kleinsasser NH, Juchhoff J, Wallner BC, Bergner A, Harréus UA, Gamarra F, Bührlen M, Huber RM and Rettenmeier AW: The use of mini-organ cultures of human upper aerodigestive tract epithelia in ecogenotoxicology. Mutat Res 561: 63-73, 2004. (Pubitemid 38845054)
48. Beck WT and Dalton WS: Mechanisms of drug resistance. In: Cancer, Principles & Practice of Oncology, 5th Edition, De Vita VT and Rosenberg HS (eds.), Lippincott-Raven p. 503, 1995.
49. Saraiya M and Kawaoka K: Incidence of human papillomavirus (HPV)-related head and neck cancers in the U.S. from 1998- 2003: Pre-HPV vaccine licensure. J Clin Oncol 25: 6003, 2007.
50. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Brichall MA and Thomas SJ: Human papillomavirus and head and neck cancer: a systematic review and meta-analyses. Clin Otolaryngol 31: 259-266, 2006. (Pubitemid 44141088)
51. Marur S, D'Souza G, Westra WH and Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic Lancet Oncol 11: 781-789, 2010.
52. Nguyen NP, Chi A, Nguyen LM, Ly BH, Karlsson U and Vinh- Hung V: Human papillomavirus-associated oropharyngeal cancer: a new clinical entity. QJM 103: 229-236, 2010.
53. Young RJ, Rischin D, Fisher R, McArthur GA, Fox SB, Peters LJ, Corry J, Lim A, Waldeck K and Solomon B: Relationship between epidermal growth factor receptor status, p16INK4A, and outcome in Head and Neck Squamous Cell Carcinoma.Cancer Epidemiol Biomark Prev 20: 1230-1237, 2011.
54. Robinson M, Sloan P and Shaw R: Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol 46: 492-496, 2012.
55. Reimers N, Kasper HU, Weissenborn SJ, Stützer H, Preuss SF, Hoffmann TK, Speel EJ, Dienes HP, Pfister HJ, Guntinas- Lichius O and Klussmann JP: Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer.Int J Cancer 120: 1731-1738, 2007. (Pubitemid 46399359)
56. Won H, Sun D, Chun S, Jeon E, Chang M, Jung C, Shim B, Lee M, Kang J and Kim J: Prognosis of HPV-positive squamous cell carcinoma of tonsil expressing high level of p16 and low level of EGFR. J Clin Oncol 28(Suppl 15): 5546, 2010.
57. Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI and Cullen KJ: Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22: 1071-1077, 2011.
58. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR and Carey TE: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 19: 3128-3137, 2008.
59. Szabó B, Nelhu{combining double acute accent}bel GA, Kárpáti A, Kenessey I, Jóri B, Székely C, Peták I, Lotz G, Hegedu{combining double acute accent}s Z, Hegedu{combining double acute accent}s B, Füle T, Döme B, Tímár J and Tóvári J: Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 47: 487-496, 2011.